Corelation Between Matrix Metalloproteinase-9 (MMP-9) With Complications of Acute Heart Failure In Myocardial Infarction With ST-Elevation (STEMI) And Acute Coronary Syndromes Without ST-Elevation (NSTEACS)

  • Budi Yuli Setianto Department of Cardiology and Vascular Medicine, Faculty of Medicine Gadjah Mada University – Dr. Sardjito Hospital Yogyakarta
  • Sofia Mubarika Department of Histology and Molecular Biology, Faculty of Medicine Gadjah Mada University
  • Indwiani Astuti Department of Pharmacology Faculty of Medicine Gadjah Mada University
  • Bambang Irawan Department of Cardiology and Vascular Medicine, Faculty of Medicine Gadjah Mada University – Dr. Sardjito Hospital Yogyakarta
DOI: https://doi.org/10.30701/ijc.v32i4.83

Abstract

Background. Acute coronary syndrome (ACS) often leads to complications of acute heart failure. These complications will increase the morbidity and mortality of patients with ACS.
Objective. To determine differences in levels of MMP-9 between STEMI and NSTEACS and the correlation between MMP-9 with acute heart failure between the two groups.
Methods. Examination of the samples performed in 79 patients with ACS (38 STEMI and 41 NSTEACS) prior to the action of intravenous thrombolytic or coronary intervention. Differences in levels of MMP-9 in the ACS are experiencing acute heart failure and without heart failure, and differences in levels of MMP-9 in the STEMI and NSTEACS groups were tested with Chi-square, Fisher’s exact test or the Independent t-test.
Results. STEMI groups had significantly higher levels of MMP-9 than NSTEACS group 1629.12 ± 719.60 compared to 1033.42 ± 777.12 (p = 0.001). However, STEMI groups who have acuteheart failure are higher but not significant compared with NSTEACS group 14 (36.84) and 11 (26.82) (p = 0.339). There are differences in levels of MMP-9 in ACS with acute heart failure than those who did not: 1698 ± 867.95 ng/mL and 1144.61 ± 713.60 ng/mL (p = 0.004).
Background. Acute coronary syndrome (ACS) often leads to complications of acute heart failure. These complications will increase the morbidity and mortality of patients with ACS.
Objective. To determine differences in levels of MMP-9 between STEMI and NSTEACS and the correlation between MMP-9 with acute heart failure between the two groups.
Methods. Examination of the samples performed in 79 patients with ACS (38 STEMI and 41 NSTEACS) prior to the action of intravenous thrombolytic or coronary intervention. Differences in levels of MMP-9 in the ACS are experiencing acute heart failure and without heart failure, and differences in levels of MMP-9 in the STEMI and NSTEACS groups were tested with Chi-square, Fisher’s exact test or the Independent t-test.
Results. STEMI groups had significantly higher levels of MMP-9 than NSTEACS group 1629.12 ± 719.60 compared to 1033.42 ± 777.12 (p = 0.001). However, STEMI groups who have acuteheart failure are higher but not significant compared with NSTEACS group 14 (36.84) and 11 (26.82) (p = 0.339). There are differences in levels of MMP-9 in ACS with acute heart failure than those who did not: 1698 ± 867.95 ng/mL and 1144.61 ± 713.60 ng/mL (p = 0.004).
Conclusion. MMP-9 levels are significantly higher in STEMI groups compared with NSTEACS groups, and MMP-9 associated with the incidence ofacute heart failure in ACS. STEMI groups have tended to have acute heart failure are higher than NSTEACS groups. MMP-9 levels are significantly higher in STEMI groups compared with NSTEACS groups, and MMP-9 associated with the incidence ofacute heart failure in ACS. STEMI groups have tended to have acute heart failure are higher than NSTEACS groups.

Downloads

Download data is not yet available.

References

Kyne, L., et al., Neutrophilia and Congestive Heart Failure after Acute Myocardial Infarction. Am Heart J, 2000. 139(1): p. 94­100.

Wilfredo, M.Y., R. Tria, and S.J.G. Abad, Absolute neutrophilia as predictor for the development of early onset Congestive Heart Failure in Patients Admitted for Acute Myocardial Infarction. PJC, 2002. 30(3): p. 101­106.

Agewall, S., Matrix metalloproteinases and cardiovascular disease. European Heart Journal, 2006. 27: p. 121­122.

Newby, A., Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerosis Plaque Rupture. Physiol Rev, 2005. 85: p. 1­31.

Amstrong, E.J., D.A. Morrow, and M.S. Sabatine, Inflamatory Biomarkers in Acute Coronary Syndromes, Part IV: Matrix Metalloproteinases and Biomarkers of Platelet Activation. Circullation, 2006. 113: p. e328­e85.

Squire, I.B., et al., Plasma MMP­9 and MMP­2 following acute myocardial infarction in man: Correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail, 2004. 10: p. 328­33.

Thygesen, K., t.J.S. Alper, and H.D. White, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J, 2007. 28: p. 2525­38.

Braunwald, E., et al., Guideline Update for the Management of Patients With Unstable Angina and Non­ST­Segment Elevation Myocardial Infarction A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina. 2002 Available from: URL http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. 2002.

PERKI, Tata Laksana Sindrom Koroner akut dengan ST­elevasi. 2004.

Alexander, R.W., T.J. Ryan, and C.M. Pratt, Diagnosis and Management of Patients with Acute Myocardial Infaction, Hurst’s The Heart, Manual of Cardiology, 2001, The McGraw­Hill Companies, Singapore.

Watanabe, N. and U. Ikeda, Matrix metalloproteinases and atherosclerosis. Curr Atheroscler Res, 2004. Mar;6(2): p. 112­120.

Libby, P. and P. Theroux, Pathophysiology of coronary artery disease. Circullation, 2005. 111: p. 3481­3488.

Ryan, T.J., et al., Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardio, 1999. l: p. 34:890 ­911.

Manginas, A., E. Bei, and A. Chaidaroglou, Peripheral Levels of Matrik Metalloproteinase­9, Interleukin­6, and C­Reactive Protein Are Elevated in Patients with Acute Coronary Syndromes: Correlations with Serum Troponin I. Clin. Cardiol, 2005. 28: p. 182­186.

Tan, J., et al., Clinical Implications of Elevated Serum Interleukin­6, Soluble CD40 Ligand, Metalloproteinase­9, and Tissue Inhibitor of Metalloproteinase­1 in Patients with Acute ST­segment Elevation Myocardial Infarction. Clin. Cardiol, 2008. 31(9): p. 413­418.

Shu, J., et al., Increased levels of interleukin­6 and matrix metallo­proteinase­9 are of cardiac origin in acute coronary syndrome. Scandinavian Cardiovascular Journal, 2007. 41: p. 149­54.

Fukuda, D., K. Shimada, and A. Tanaka, Comparison of Levels of Serum Matrik Metalloproteinase­9 in Patients With Acute Myocardial Infarction Versus Unstable Angina Pectoris Versus Stable Angina Pectoris. Am J Cardiol, 2006. 97: p. 175­180.

Phatharajaree, W., A. Phrommintikul, and N. Chattipakorn, Matrix metalloproteinases and myocardial infarction. Can J Cardiol, 2007. 23(9)(9).

Antman, E. and E. Braunwald, Acute Myocardial Infarction. In: Heart Disease: A textbook of Cardiovascular Medicine, 2001, WB Saunders Philadelphia. p. 1140­1162.

Herzog, E., et al., Early activation of metalloproteinases after experimental myocardial infarction occurs in infarct and non­infarc zones. Cardiovasc Pathol, 1998. 84: p. 307­12.

Etoh, T., et al., Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol, 2001. 281: p. 987­994.

Jong, G.P., et al., Serum MMP­9 Activity as a Diagnosing Marker for the Developing Heart Failure of Post MI Patients. Chinese Journal of Physiology, 2006. 49(2): p. 104­109.
Views & Downloads
Abstract views: 3074   
PDF (Bahasa Indonesia) downloads: 2011   
How to Cite
Setianto, B., Mubarika, S., Astuti, I., & Irawan, B. (1). Corelation Between Matrix Metalloproteinase-9 (MMP-9) With Complications of Acute Heart Failure In Myocardial Infarction With ST-Elevation (STEMI) And Acute Coronary Syndromes Without ST-Elevation (NSTEACS). Indonesian Journal of Cardiology, 32(4), 229-35. https://doi.org/10.30701/ijc.v32i4.83
Issue
Vol. 32, No. 4 Oktober - Desember 2011
Section
Clinical Research

Authors who publish with this journal agree to the following terms:

    • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).